Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 14,746 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pulmonary Clear all

Conditions: SARS-CoV-2 Infection
Interventions: COVID-HIG; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Springfield, Missouri

Conditions: Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Inivata; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 35
States / cities: Mission Hills, California • Aurora, Colorado • Norwich, Connecticut + 32 more

Conditions: Carcinoma, Non-small-cell Lung
Interventions: TLK286; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 3
States / cities: Tucson, Arizona • Los Angeles, California • Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab; Drug
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 15
States / cities: Duarte, California • Fort Wayne, Indiana • Goshen, Indiana + 9 more

Conditions: Asthma
Interventions: Montelukast, Sugar pill; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Inoperable Stage I/II Non-small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT); Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Electronic Cigarette Use
Interventions: Health Assessments; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pulmonary Hypertension, Heart Failure, Single Ventricle
Interventions: Actigraph to check activity levels at home; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 18 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions: Atorvastatin and Lisinopril, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pulmonary Ventilation, Capnography
Interventions: Linshom Respiratory Monitoring Device; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
Interventions: ADXS-503, Pembrolizumab; Drug
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more

Conditions: Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
Interventions: Binimetinib, Palbociclib, Therapeutic Conventional Surgery; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 40
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Conditions: Non-Small-Cell Lung Cancer
Interventions: Enhanced Care (intervention group and comparison group), Usual care (routine chemotherapy cycles and imaging studies); Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: Not listed
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Acute Pulmonary Embolism
Interventions: Healthy Living Intervention-1, Healthy Living Intervention-2; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Congestive Heart Failure(CHF), Pulmonary Edema
Interventions: Pulmonary ultrasound; Diagnostic Test
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Newark, Delaware • Newark, New Jersey

Conditions: Covid19, SARS-CoV Infection
Interventions: Sargramostim, Placebo; Drug
Lead sponsor: Partner Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more

Conditions: Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: Dexmedetomidine, Midazolam and Fentanyl; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Bronchiolitis Obliterans
Interventions: Hp 129Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: COPD
Interventions: Use of Telehealth equipment (Viterian V-100); Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Omaha, Nebraska

Conditions: HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
Interventions: GQ1001; Drug
Lead sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm
Interventions: Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: PH-797804, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 22
States / cities: Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more

Conditions: Pulmonary Arterial Hypertension
Interventions: GB002 (seralutinib), Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: Gossamer Bio USA, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more

Search by objective public record fields.

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing

Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

Moderate to Persistent Asthma in the Obese Subject

A Phase I/II Trial of Stereotactic Body Radiation Therapy

Effects of E-cigarette Use on Health

Frailty in Children With Cardiac Disease

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Non-invasive Tidal Volume Monitoring Using the Linshom Respiratory Monitoring Device

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis

Lung Cancer Information Study (LCIS-R01)

Incorporating Healthy Living Strategies to Aid in Recovery After Acute Pulmonary Embolism

Evaluating the Use of Prehospital Lung Ultrasound in EMS: A Multicenter Pilot Study

Sargramostim Use in COVID-19 to Recover Patient Health

Sleep Intervention During Acute Lung Injury

Hp129 Xenon Imaging and BOS in Lung Transplantation

VISN 23 Chronic Obstructive Pulmonary Disease (COPD) Case Management Using Home Telehealth Equipment

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)